Volpato, MileneCummings, MicheleShaaban, Abeer MAbderrahman, BalkeesHull, Mark AMaximov, Philipp Y.Broom, Bradley M.Hoppe, ReinerFan, PingBrauch, HiltrudJordan, V CraigSpeirs, Valerie2021-03-232021-03-232020-10-30Volpato, M, Cummings, M, Shaaban, A M, Abderrahman, B, Hull, M A, Maximov, P Y, Broom, B M, Hoppe, R, Fan, P, Brauch, H, Jordan, V C & Speirs, V 2020, 'Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer', Exploration of Targeted Anti-tumor Therapy, vol. 1, pp. 355-371. https://doi.org/10.37349/etat.2020.000212692-3114ORCID: /0000-0002-0602-4666/work/82658896https://hdl.handle.net/2164/16111Acknowledgments We thank Werbena Hamilton-Burke, Loaie Maraqa and Mark Peter for providing clinical data on the breast tumours which populated the TMAs used in this study. Funding: This work was supported in part by Cancer Research UK grant C13432/A9047; Yorkshire Cancer Research grant L314; the Robert Bosch Foundation, Stuttgart, Germany; the NIH; MD Anderson’s Cancer Center support grant CA016672; the George and Barbara Bush Foundation for Innovative Cancer Research; and the Dallas/Fort Worth Living Legend Chair of Cancer Research. The study sponsor(s) played no part in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication.174861841engSDG 3 - Good Health and Well-beingBreast cancerendocrine resistance15-hydroxyprostaglandin dehydrogenaseimmunohistochemistrysurvivalR MedicineCancer Research UKC13432/A9047Supplementary DataRJournal article10.37349/etat.2020.000211